Allopurinol hypersensitivity reactions: Desensitization strategies and new therapeutic alternative molecules

Gianfranco Calogiuri, Eustachio Nettis, Elisabetta Di Leo, Caterina Foti, Antonio Ferrannini, Lavjay Butani

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Allopurinol, an analog of hypoxanthine has been worldwide used for the treatment of hyperuricemia and gout for over 40 years. Unfortunately some patients assuming this medication have developed hypersensitivity reactions ranging from mild cutaneous eruption to more severe clinical manifestations such as allopurinol hypersensitivity syndrome or Steven-Johnson syndrome and lethal toxic epidermal necrolysis. Various strategies of slow desensitization have been elaborated to reintroduce allopurinol in a part of these patients, mainly patients affected by mild skin reactions as fixed drug eruption or exanthema. However, several new uricosuric therapies have been recently introduced. Actually drugs as recombinant urate oxidase and febuxostat are under post-marketing surveillance to control potential adverse effects related to their immunogenicity even.

Original languageEnglish (US)
Pages (from-to)19-28
Number of pages10
JournalInflammation and Allergy - Drug Targets
Issue number1
StatePublished - 2013


  • Allopurinol
  • Anakinra
  • Desensitization
  • Febuxostat
  • Hypersensitivity
  • Rasburicase

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology


Dive into the research topics of 'Allopurinol hypersensitivity reactions: Desensitization strategies and new therapeutic alternative molecules'. Together they form a unique fingerprint.

Cite this